Holen Sie sich die Stockscreener-App
0.3503
7.03%
-0.0265
Handel nachbörslich:
.34
-0.0103
-2.94%
Schlusskurs vom Vortag:
$0.3768
Offen:
$0.3703
24-Stunden-Volumen:
490.19K
Relative Volume:
1.47
Marktkapitalisierung:
$11.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-0.4754
EPS:
-0.7368
Netto-Cashflow:
-
1W Leistung:
-14.64%
1M Leistung:
-29.07%
6M Leistung:
-83.48%
1J Leistung:
-88.32%
1-Tages-Spanne:
$0.3401
$0.3796
1-Wochen-Bereich:
$0.3401
$0.44
52-Wochen-Spanne:
$0.3401
$3.89
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Firmenname
Calidi Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 794-9600
Adresse
4475 Executive Drive, Suite 200, San Diego
Vergleichen Sie CLDI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.3503 | 13.05M | 0 | -23.36M | 0 | -0.7368 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-09 | Eingeleitet | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
Calidi Biotherapeutics (NYSE:CLDI) Shares Down 5.3% – Time to Sell? - Defense World
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results And Recent Operational Highlights - marketscreener.com
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewswire
Calidi Biotherapeutics Secures FDA Green Light for Cancer Trial as New CEO Reveals Q1 Financials - Stock Titan
Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World
Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World
Investor’s Delight: Calidi Biotherapeutics Inc (CLDI) Closes Weak at 0.65, Down -6.53 - DWinneX
Calidi (CLDI) Advances Cancer Treatment with IL15 Superagonist a - GuruFocus
Calidi Biotherapeutics Announces IL15 Superagonist as First - GlobeNewswire
Revolutionary Cancer Treatment Platform Shows Complete Tumor Elimination: First Systemic Delivery Success - Stock Titan
Calidi Biotherapeutics (CLDI) Awards Stock Option to New CEO Eri - GuruFocus
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi Bio's Strategic Move: New CEO Secures 726K Share Options with 4-Year Performance Lock - Stock Titan
Calidi Biotherapeutics appoints new CEO By Investing.com - Investing.com South Africa
Zealand names former Lilly exec Singh as CSO - BioCentury
Calidi Biotherapeutics appoints new CEO - Investing.com
Calidi (CLDI) Appoints New CEO as Eric Poma Assumes Leadership | - GuruFocus
Calidi Biotherapeutics Appoints New CEO Eric Poma - TipRanks
Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director - TradingView
Calidi Biotherapeutics Announces Chief Executive Officer - GlobeNewswire
New Calidi Bio CEO Brings $400M Funding Success Record: Strategic Shift for Cancer Treatment Pioneer - Stock Titan
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor - The Globe and Mail
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 - The Manila Times
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24 - GlobeNewswire
Cancer Breakthrough Alert: Top Oncologist Reveals New FDA-Cleared Stem Cell Therapy Development - Stock Titan
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors - The Manila Times
FDA Green Lights Revolutionary Cancer Treatment: Stem Cells Combined With Virus to Fight Multiple Tumors - Stock Titan
Calidi Biotherapeutics Announces Appointment of Guy Travis - GlobeNewswire
Cancer Drug Developer Calidi Bio Strengthens Leadership: Renowned Oncologist Takes CMO Role - Stock Titan
Calidi Biotherapeutics Appoints New Chief Medical Officer - TipRanks
CLDI stock touches 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa
CLDI stock touches 52-week low at $0.42 amid market challenges - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
HighTower Advisors LLC Makes New Investment in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - The Manila Times
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges By Investing.com - Investing.com South Africa
Calidi Bio Raises Fresh $3.9M Capital to Advance Clinical Programs - Stock Titan
Calidi Biotherapeutics Cuts Losses by 50% While Expanding Cancer Gene Therapy Trials - Stock Titan
CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com India
Virtu Financial LLC Buys Shares of 73,448 Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics sinks after pricing $3.9M registered direct offering - MSN
Calidi prices 3.33M shares at 65c in registered direct offering - TipRanks
Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
Kapitalisierung:
|
Volumen (24h):